RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
Rhea-AI Summary
RxSight (NASDAQ: RXST) announced that its management will participate in the Wells Fargo Healthcare Conference in Boston, Massachusetts, on Wednesday, September 9, 2026, at 9:30 a.m. ET. A live and archived webcast of the presentation will be accessible via the company’s investor relations website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 05 | Earnings report | Negative | -3.3% | Product sales declined and 2026 guidance was withdrawn amid the leadership transition. |
| Jul 26 | Equity awards | Neutral | +8.7% | CEO inducement options and RSUs were granted under Nasdaq rules. |
| Jul 15 | Leadership change | Positive | +6.1% | Mottiwala became CEO while Kurtz continued as chief medical officer. |
| Jul 06 | Preliminary results | Neutral | +0.4% | Mixed results included lower sales guidance and higher gross-margin guidance. |
| Jul 06 | Alcon collaboration | Positive | +0.4% | Agreement included a $60 million upfront payment, milestones, and royalties. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent reactions were positive for leadership and equity-award announcements but negative after the latest earnings report.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company’s investor relations website at https://investors.rxsight.com/.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com
